Skip to main content
Clinical Trials/CTRI/2018/05/014152
CTRI/2018/05/014152
Completed
Phase 2

Evaluation of Safety and efficacy of two different Unani compound formulations UNIM 401 (O) and UNIM 403 (L) with Munzij Mushil therapy in cases of Daus Sadaf (Psoriasis) - PSO/CS-2

Central Council for Research in Unani Medicine0 sites120 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: null- Psoriasis
Sponsor
Central Council for Research in Unani Medicine
Enrollment
120
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
January 20, 2017
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Apparent psoriatic lesions of the body

Exclusion Criteria

  • 1\. Patients with psoriatic arthritis
  • 2\. Patients suffering with other skin diseases
  • 3\. Serious systemic diseases
  • 4\. Pregnant and lactating mothers
  • 5\. Patient unsure about attending treatment schedule regularly and those who do not have a suitable place for sun exposure

Outcomes

Primary Outcomes

Not specified

Similar Trials